(c) 2024 PillSync.com

atorvastatin calcium 20 mg

1 INDICATIONS AND USAGE Atorvastatin Calcium Tablets are indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia Atorvastatin calcium tablet is an HMG-CoA reductase inhibitor (statin) indicated ( 1 ): To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia. As an adjunct to diet for the treatment of adults with: Primary dysbetaliproteinemia. Hypertriglyceridemia.

ScieGen Pharmaceuticals, Inc.


3 hours ago OVAL YELLOW SG 153 atorvastatin calcium 20 mg

OVAL YELLOW SG 153

3 hours ago OVAL YELLOW SG 153 atorvastatin calcium 20 mg

SG 153 OVAL YELLOW

16 HOW SUPPLIED/STORAGE AND HANDLING

ATORVASTATIN CALCIUM Tablets, USP are supplied as follows: Strength How Supplied NDC Tablet Description 10 mg of atorvastatin bottles of 90 50228-451-90 yellow, oval shape, biconvex, film coated tablets, debossed with SG on one side and 152 on other side bottles of 1,000 50228-451-10 20 mg of atorvastatin bottles of 90 5022-452-90 yellow, oval shape, biconvex, film coated tablets, debossed with SG on one side and 153 on other side bottles of 500 5022-452-05 40 mg of atorvastatin bottles of 90 50228-453-90 yellow, oval shape, biconvex, film coated tablets, debossed with SG on one side and 154 on other side bottles of 1,000 50228-453-10 80 mg of atorvastatin bottles of 90 50228-454-90 yellow, oval shape, biconvex, film coated tablets, debossed with SG on one side and 155 on other side bottles of 500 50228-454-05 Storage Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispense in a tight, child-resistant container.


More pills like OVAL SG 153

Related Pills

atorvastatin 10 mg

sciegen pharmaceuticals, inc.

atorvastatin 40 mg

sciegen pharmaceuticals, inc.

atorvastatin 20 mg

Cipla USA Inc.,

atorvastatin 20 mg

Cipla USA Inc.,

atorvastatin 20 mg

cipla usa inc.,

atorvastatin 20 mg

cipla usa inc.,












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site